Mati Therapeutics Inc.

Medtronic, Inc.

Emphasys Medical, Inc.

Qlt Inc.

Ventrica, Inc.

Pulmonx Corporation

Alan R Rapacki

Hanson S Gifford, Iii

Hanson Gifford

Cary J Reich

Eugene De Juan, Jr

Mark E Deem

Stephen A Boyd

Darin Charles Gittings

Valery Rubinchik

Ronald Ray Hundertmark

Gilbert S Laroya

Sylvie Sim

Danny Shen

John B Holds

Dean F Carson

Michael Barrett

Peter M Wilson

Antony Jonathan Fields

A Adam Sharkawy

Mark J Foley

Wally S Buch

Michael J Hendricksen

Keke Lepulu

Bernard H Andreas

Douglas Sutton

David H Cole

Ronald G French

David R Tholfsen

Sunmi Chew

John G McCutcheon

Charles Richard Kjellbotn

Adam Sharkawy

Charles R Kjellbotn

Douglas S Sutton

Robert George

Jeffrey J Dolin

Anton J Fields

Wilhelm Leung

Michael J Hendrickson

Donald Sutton

Cary Reich

Hanson S Gifford

John G Mccutcheon

Michael S Barrett

Mark Deem

Stephen Boyd

Mccutcheon John

Jeffrey Dolin

Jr Eugene De Juan

Robert M George

Bernard Andreas

An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.

Nasolacrimal drainage system implants for drug therapy

Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.

Lacrimal implants and related methods

Lacrimal implants and related methods providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants can comprise an implant body configured for at least partial insertion through the lacrimal punctum and into the canaliculus. The implant body can include first and second portions, and can extend from a proximal end of the first portion defining a longitudinal proximal axis to a distal end of the second portion defining a longitudinal distal axis. The implant body can be configured such that, when implanted using an integral dilator, an angled intersection exists between the proximal and distal axes. In this way, at least a portion of the implant body can be biased against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature, thereby retaining an implanted position of the lacrimal implant using anatomical structures.

Scleral and conjuctival implants for drug therapy

Growing community of inventors

Redwood City, CA, United States of America

Alan R Rapacki